Registry update — unassessed
Metformin and Muscle in Insulin-resistant Older Veterans
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Feb 11, 2020 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract contains no data on whether metformin actually affected muscle mass, strength, or function.
- Sample size is not reported, making it impossible to assess statistical power or whether this was adequately powered to detect a clinically meaningful difference.
- The abstract does not report whether any adverse events, adherence rates, or other safety concerns were observed.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- VA Office of Research and Development
- Published
- Feb 11, 2020
Sources
Primary source
- VA Office of Research and Development ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Sarcopenia is the loss of muscle mass, strength and function with aging and is associated with increased disability, falls and fractures.
Older adults with diabetes and prediabetes are insulin resistant and have a higher risk of developing sarcopenia.
This study examines the use of metformin, an antidiabetic drug, for preventing the development of sarcopenia in older adults with prediabetes.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.